drugset

drugset / Trial / NCT05849727

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

NCT05849727 ↗

Phase 2 Terminated 195 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of TQH3821 in treated patients with moderate-to-severe active rheumatoid arthritis.

Timeline

Start: 2023-08-30
Primary completion: 2025-01-15
Completion: 2025-01-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQH3821	Unknown	200 mg	Oral

Indications